Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the low efficacy rates of the AstraZeneca vaccine against the B.1.351 variant, with repeated references to figures like '10.4%' efficacy mentioned across various posts. The tone often shifts towards urgency and concern as users argue about the vaccine's effectiveness, using phrases like 'not effective enough' and 'serious implications for public health,' which conveys a deep sense of urgency regarding vaccination strategies.
The majority of posts express strong skepticism or disagreement with the vaccine's efficacy, questioning health authorities and research outcomes.
Discussion shows high levels of curiosity and relevance to the community, as many users cite specific studies and data.
There are numerous references to studies, efficacy data, and critical scientific analyses, indicating deep engagement with the subject matter.
Users perceive the findings and discussions to have significant implications for public health and vaccination strategies.
Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse tautia vastaan oli 79% ja vakavaa tautimuotoa vastaan 100%. Todellisuudessa tutkimuksetkin antoivat vain 10 prosentin tehon. https://t.co/pjHBXicV0E Nohynek siis https://t.co/aNo1chjHyX https://t.co/uL3iYZqfdA
This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 among people infected with the B.1.351 variant in a multicenter randomized trial in South Africa." https://t.co/37JPxvdmNT
@Sven__Weiss @ZweitAcccount @MarkelGerald https://t.co/4dee8bwBd8 https://t.co/4dee8bwBd8 https://t.co/0Ip3PtDnCe https://t.co/QfJiSsRGEo https://t.co/rIYWbUTzvw https://t.co/CIVIPmaI0a
Şu ana kadar tanımlananlar içinde V2 varyantı aşılardan en fazla kaçabilen varyant. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/Wf4qCEFvVq
アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得られなかった。
>>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten inenten. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/wwI7iD1oUt
The study examines the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in South Africa, specifically its effectiveness against the B.1.351 variant. Results indicate a vaccine efficacy of 21.9% against symptomatic…
In this talk, I discuss in detail how vaccines are useful in fighting COVID-19 and their role in preventing future pandemic waves. This includes analysis of the ChAdOx1 nCoV-19 vaccine's efficacy against the B.1.351…
@grok @DrNeilStone @grok you have been reset, haven’t you? COVID wastewater September 2019 Italy https://t.co/rYtAW5CCrT B.1.351 with its immune escape mutations likely in circulation as early as June 2020 https://t.co/5QELStmb16 With limited to no testing with no genomic sequencing during
@Marcabe71 It’s far from the best I have. Don’t associate me with a colour or a side. “Vaccine” efficacy was as low as 10.4% before en-masse release to the public; https://t.co/5QELStmb16 https://t.co/q7mRIJC9vl
@grok @xai @grok let’s remind you that B.1.351 was on the African continent during 2020, as the Gates Foundation-funded study that appeared in NEMJ will contest. (N Engl J Med 2021;384:1885-1898 DOI: 10.1056/NEJMoa2102214) Your claim that it wasn’t in Africa until 2021 is inaccurate. Please
@grok @xai @grok let’s remind you as you try to backpedal that B.1.351 was on the African continent during 2020, as the Gates Foundation-funded study that appeared in NEMJ will contest. (N Engl J Med 2021;384:1885-1898 DOI: 10.1056/NEJMoa2102214) Your claim that it wasn’t in Africa until
@Chrystalos @DrNeilStone When the preprint emerged for AstraZeneca which showed just 10.4% efficacy due to globally circulating immune escape mutations during 2020 and the fact that the RCT was stopped due to safety concerns over transverse myelitis. https://t.co/5QELStmb16
@BlistexFace @grok @DrNeilStone https://t.co/5QELStmb16
@TgdxbBru @RedPandaPills @machi_buse Vous expliquez n’importe quoi. Par exemple, une branche de l’essai clinique du vaccin contre le Covid d’Astra Zeneca a été réalisée en double aveugle. https://t.co/NUE5djFEJ8 https://t.co/6qKb9nMslo
@grok @KEriksenV2 @grok Why are you lying? The study below proved that B.1.351 with its mutations rendered the efficacy of AstraZeneca at 10.4%. This is why the WHO labelled B.1.351 a VOC before the vaccines were released to the public Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
RT @petteri_vaara: Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse taut…
Ensin THL ja sen asiantuntijat puhuivat ihan puutaheinää näiden myrkkypiikkien tehosta. Nohynekin mukaan suoja itse tautia vastaan oli 79% ja vakavaa tautimuotoa vastaan 100%. Todellisuudessa tutkimuksetkin antoivat vain 10 prosentin tehon. https://t.co/pjHBXicV0E Nohynek siis https://t.co/aNo1chjHyX https://t.co/uL3iYZqfdA
@spicypiscespdx @DrNeilStone Start here… https://t.co/5QELStmb16 https://t.co/iuSFZwPbtR
@Grandroyal11 @simonmaechling https://t.co/5QELStmb16
RT @BarryESharp: Post 6. - Efficacy Data: - AstraZeneca’s 10.4% efficacy against Beta (*NEJM*, 2021, DOI: 10.1056/NEJMoa2102214). -…
Post 6. - Efficacy Data: - AstraZeneca’s 10.4% efficacy against Beta (*NEJM*, 2021, DOI: 10.1056/NEJMoa2102214). - mRNA vaccines’ 23.5% efficacy against Omicron infection (*The Lancet Infectious Diseases*, 2022, DOI: 10.1016/S1473-3099(22)00146-3). - Vaccines failed to
@chris_komatsu Has it sunk in how utterly misinformed you were, yet? https://t.co/5QELStmb16 https://t.co/AcZhKHgK14 https://t.co/a45fTlmmuw
@caintoko @MarkJCarney https://t.co/5QELStlDby https://t.co/AcZhKHgcbw
@MatterRichLives @DrNeilStone You can start here and do your own research; https://t.co/5QELStmb16
@neildrewitt @Telegraph https://t.co/5QELStmb16
@JenniBeTweets @Ron_Welsh398 @DrNeilStone https://t.co/5QELStmb16
@alanlremick @skepticalraptor It really wasn’t effective and this was known before it was released; https://t.co/5QELStmb16
@dense_evi https://t.co/5QELStmb16
RT @BarryESharp: @Truth_in_Number https://t.co/5QELStlDby
RT @BarryESharp: @Truth_in_Number https://t.co/5QELStlDby
RT @BarryESharp: @Truth_in_Number https://t.co/5QELStmb16
@labsarekindest @SAntiochis @DrNeilStone What lies, Lucas? Efficacy 10.4% inconclusive against severe disease https://t.co/5QELStmb16
@error9900 @IanCopeland5 https://t.co/5QELStmb16
@Truth_in_Number https://t.co/5QELStmb16
@Truth_in_Number https://t.co/5QELStlDby
@Truth_in_Number https://t.co/5QELStlDby
@themuso2008 @DrNice2022 @IntegralAnswers 10.4% https://t.co/5QELStlDby
@Solahmi_ @DrNice2022 You caught AI lying about the study, hilarious and you fell for it https://t.co/5QELStlDby
@Solahmi_ @DrNice2022 LMFAO, you caught AI lying, hilarious https://t.co/5QELStlDby
@Solahmi_ @DrNice2022 The study https://t.co/5QELStlDby
@Solahmi_ @DrNice2022 https://t.co/5QELStlDby
@Tanto_Archilo @DrNeilStone @CommunityNotes Start here with B.1.351 https://t.co/5QELStmb16 Covid Italy September 2019 https://t.co/rYtAW5CCrT
@Tanto_Archilo @DrNeilStone @CommunityNotes Then you will have to rely upon your own investigative skills, won’t you? You can start here with B.1.351 https://t.co/5QELStmb16
@vjhoodlander B.1.351, Gates Foundation Funded Study, South Africa, AstraZeneca 10.4% efficacy against mild to moderate disease, inconclusive against severe disease https://t.co/5QELStmb16
@Markus_Flauschi @dense_evi @hisoandso Why don’t you start with the failure of AstraZeneca in trials against B1.351 due to the immune escape mutation K417n? https://t.co/5QELStmb16
@BarryESharp "Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, −76.8 to 54.8)." Look at that CI! https://t.co/etHbR6wzn3
@Jimmy78591 https://t.co/5QELStlDby
@ErikCumps @MauritzPreller @PaCardiology Is that right? https://t.co/jSwSaDTY79 Grok response to https://t.co/5QELStmb16
@MauritzPreller https://t.co/5QELStmb16
@Creativologist @Brewbits22 @Debunk_the_Funk Stupid fuckwit, B.1.351 contained the immune escape mutationK417n. It just shows how misinformed you are and how wrong the crap that you rely on truly is. https://t.co/5QELStlDby
@Creativologist @Brewbits22 @Debunk_the_Funk LMAO, you can't even get that right. https://t.co/5QELStlDby
@D2R67 @q2kxzy6ysb1 @yay_its_james 10.4% efficacy during trials, could not prevent mild or moderate disease and was inconclusive against severe disease, let’s release it anyway; https://t.co/XSMT10eAJ0
@FactsAreGood @yay_its_james https://t.co/XSMT10e2Ts
RT @Unheilpraktiker: @Sven__Weiss @ZweitAcccount @MarkelGerald https://t.co/4dee8bwBd8 https://t.co/4dee8bwBd8 https://t.co/0Ip3PtDnCe h…
@Sven__Weiss @ZweitAcccount @MarkelGerald https://t.co/4dee8bwBd8 https://t.co/4dee8bwBd8 https://t.co/0Ip3PtDnCe https://t.co/QfJiSsRGEo https://t.co/rIYWbUTzvw https://t.co/CIVIPmaI0a
RT @BarryESharp: @Reactively @NateB_Panic Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking stu…
@Reactively @NateB_Panic Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
RT @BarryESharp: Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Fo…
@COVID19_disease Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
@BNOFeed Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
@EnemyInAState Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
RT @BarryESharp: Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Fo…
@outbreakupdates Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
@zap_lock Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
RT @BarryESharp: Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Fo…
Title: Understanding the K417n Mutation: How it Impacts our Immune Response A groundbreaking study funded by the Gates Foundation, titled "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant," began in South Africa back in June 2020, even before the
RT @oneadds: Right yeah but after you have got someone to design your poison you still have to get it through Clinical trials.. No problem…
Right yeah but after you have got someone to design your poison you still have to get it through Clinical trials.. No problem.. Just fund them!! https://t.co/LepU8i0U8x https://t.co/kAPTp1lxmn, https://t.co/kAPTp1lxmn https://t.co/QLsQfYoNjY https://t.co/4JCbAfYBYv
@Prolotario1 @ninoboxer https://t.co/YP2jueGJOk
12/21 Se você ainda não está satisfeito, também pode ir conferir os artigos da AstraZeneca (inclusive dos estudos que incluíram os brasileiros) https://t.co/s2q43ngXMB https://t.co/UoumecCnWW Ou da Janssen tbm https://t.co/eTaHXl4ViL E da CovLP https://t.co/TsPtqpCe7A https://t.co/PXz4ghmCVJ
RT @_chAyA_: https://t.co/VNmInkydky why did they test astrazeneca on HIV-negative adults ;-) u geniuses know? @UnSubtleDesi @opindia_com…
https://t.co/VNmInkydky why did they test astrazeneca on HIV-negative adults ;-) u geniuses know? @UnSubtleDesi @opindia_com @abhishbanerj cc @DeeEternalOpt https://t.co/HMC2GOjw2K
RT @Shorty56167141: This noise doesn't add up...
This noise doesn't add up...
@zet_mood @ben_ben_fr https://t.co/JU4JwZG56R Financée par La Fondation Bill et Melinda Gates (
@SenRonJohnson Here are some drug facts, Sen. Johnson, for the record: https://t.co/EujhvJSFQ8; https://t.co/Xiy5jzfPoc; https://t.co/DDYCtmuFis. Questions now about monkeypox & chimpanzee-based vaccines (ChAdOx). https://t.co/OM9hjIbgGX Much to question about the data, studies & aggressiveness
RT @terra_cremada: ℹ️Un règim de dues dosis de la vacuna ChAdOx1 nCoV-19 no va mostrar protecció contra Covid-19 lleu a moderada a causa de…
RT @terra_cremada: ℹ️Un règim de dues dosis de la vacuna ChAdOx1 nCoV-19 no va mostrar protecció contra Covid-19 lleu a moderada a causa de…
RT @terra_cremada: ℹ️Un règim de dues dosis de la vacuna ChAdOx1 nCoV-19 no va mostrar protecció contra Covid-19 lleu a moderada a causa de…
ℹ️Un règim de dues dosis de la vacuna ChAdOx1 nCoV-19 no va mostrar protecció contra Covid-19 lleu a moderada a causa de la variant B.1.351. (Finançat per la Fundació Bill i Melinda Gates i altres; número de https://t.co/InN3nr6dn7, NCT04444674 https://t.co/13Ooiw5SRF
@AmyJacobson @MorningAnswer Read about it before you go blurting it out as an emergency to people who don't even bother with anything the CDC or NIH say anymore. https://t.co/ztHUeaRAlC https://t.co/d9Hai3CjgC https://t.co/NOWwwp9hKV https://t.co/f68W0XiC5i https://t.co/OM9hjIaIRp
@CNNPolitics Right back at you, electronic bullies. Read about it. https://t.co/ztHUeaRAlC https://t.co/d9Hai3CjgC https://t.co/NOWwwp9hKV https://t.co/f68W0XiC5i https://t.co/OM9hjIaIRp
@seattletimes Where are you getting your data from? Read these before you push another false emergency. Monkey to smallpox very suspicious references. https://t.co/ztHUeaRAlC https://t.co/d9Hai3CjgC https://t.co/NOWwwp9hKV https://t.co/f68W0XiC5i https://t.co/OM9hjIaIRp
@sailorrooscout @JackTors11245 I'll just leave this here. https://t.co/UE3TK9iAEZ
@JackTors11245 @CHSpolitico @JakeAnbinder Not any more, and it won't get better, resistance will grow the more the ineffective vax is used. Well known for many decades. https://t.co/x49SFinHl4
@wendy_harmer Thanks for the info Wendy, here's some of the latest on how ineffective vaccines are against Omicron, not antvax rot. Real science. https://t.co/UE3TK9iAEZ
@EssexPR
@toadmeister
@bobepidemiology Yep and I agree it's not clearly different from those graphs which is terrific. The amount of stupid negative attention AZ got based on this study https://t.co/LdCKktJc1X was just
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. The research shows that only after few months, all kinds of vaccines will lose its efficacy. https://t.co/C4GGO45k8U
@hotradero Kalau seneng baca-baca, mungkin boleh dibaca soal berapa persen efikasi AstraZeneca terhadap COVID, yang membuat analogi naik pesawat vs. jalan kaki menjadi sangat jauh. https://t.co/C4GGO45k8U
RT @carpe_diem0820: 南アフリカでHIV陰性成人2026人でアストラゼネカワクチンの評価 軽-中等症の COVID-19予防の有効率は 21.9% ワクチン接種群の感染は39/42名(92.9％)がB.1.351変異株によるもの 有効性は10.4% Effi…
RT @ERxICU_yakkun: アストラゼネカワクチンは南ア変異株に効かんのか… Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.…
RT @georgebest1969: アストラゼネカのワクチン、南アフリカの変異株で効果示さず。 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https…
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
RT @j_sato: ベータ・南ア株にAZ
@kitamu_cho 他のサイトでも同じ内容です アストラゼネカ社COVID-19ワクチンは南アフリカB.1.351バリアントに著効なし Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/BugJlsFRF9 罹患者の95.1%はB.1.351バリアントによるもので、同株に対するワクチン有効率は10.4%
RT @Q3QTV8SiVUhbwBN: @j_sato @NY3DurZyXlMQWOp @rocky13396300 @hudikaha 他のサイトでも同じ内容です アストラゼネカ社COVID-19ワクチンは南アフリカB.1.351バリアントに著効なし Efficacy o…
RT @Q3QTV8SiVUhbwBN: @j_sato @NY3DurZyXlMQWOp @rocky13396300 @hudikaha 他のサイトでも同じ内容です アストラゼネカ社COVID-19ワクチンは南アフリカB.1.351バリアントに著効なし Efficacy o…
@j_sato @NY3DurZyXlMQWOp @rocky13396300 @hudikaha 他のサイトでも同じ内容です アストラゼネカ社COVID-19ワクチンは南アフリカB.1.351バリアントに著効なし Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/BugJlsFRF9 罹患者の95.1%はB.1.351バリアントによるもので、同株に対するワクチン有効率は10.4%
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/EOf34KTVfO Vaccine efficacy against beta variant and why we should stay cautious
RT @jinichimori: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM アストラゼネカのワクチン、南アフリカ変異株に無効という論文出たその日に日本…
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/ruERmmV479
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/dnd7lpMSbd
@asteroidsletter @gabriel_andrew8 @NaturebaReal @dogarrett "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM" https://t.co/SW57wGfKCo
AstraZeneca社製以外のワクチンの有効性はどんな感じなのでしょうか。ファイザー社製は重症化を防ぐ効果があるということですが。 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/V2MGmylpqM
Bad news. Apuremos la vacunación. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/fcM9LqdH63
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @RegaCarlos: Debemos extremar los controles fronterizos. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant |…
แปะไว้ก่อนเดี๋ยวมาอ่านเปเปอร์เรื่องวัคซีน Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/XYpBInP1PS
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/BrpJCCQOgO
อ.ยง อ่านเปเปอร์นี้หรือยังครับ | Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/kmiww9gybW
Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. NEJMoa2102214 (2021) doi:10.1056/NEJMoa2102214.
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
RT @MerlotVine: >>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten i…
>>> @hugodejonge, @MinVWS, @tamaravanark , wat gaan jullie doen? Jullie hebben drie risicogroepen met dit vaccin in laten inenten. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/wwI7iD1oUt
Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant … https://t.co/ho0aa4Uon6
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @KFSHRC_Research: Efficacy of the ChAdOx1 nCoV-19 #Covid_19 Vaccine against the B.1.351 Variant https://t.co/ea63CYyRhO https://t.co/QzN…
Efficacy of the ChAdOx1 nCoV-19 #Covid_19 Vaccine against the B.1.351 Variant https://t.co/ea63CYyRhO https://t.co/QzNVx0LDYP
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM - https://t.co/sYLVbTPBJo - null :: Source: https://t.co/dLRtd5GOTF
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/RUwwP53AXw
RT @serapsimsekyvz: Şu ana kadar tanımlananlar içinde V2 varyantı aşılardan en fazla kaçabilen varyant. Efficacy of the ChAdOx1 nCoV-19 Cov…
Şu ana kadar tanımlananlar içinde V2 varyantı aşılardan en fazla kaçabilen varyant. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM https://t.co/Wf4qCEFvVq
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
RT @minesoh: NEJM
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/xzJmkJigHZ
RT @syuichiao89: 本日の論文▶https://t.co/139Tl0zgPZ / @89089314 https://t.co/esTEagOxBK
本日の論文▶https://t.co/139Tl0zgPZ / @89089314 https://t.co/esTEagOxBK
https://t.co/nI5WD0UA8f
@sanchak74 There was reason to slightly worry. B.1.1.7 replaced all the old variants during their second wave. Meanwhile, Oxford/AZ vaccination showed reduced neutralizing efficiency with B.1.351 that was dominating SA https://t.co/yFQzTszzt7. The UK went into lockdown during vaccination
@Capt_Shalini It may be true as this virus is capable of tweaking it's spike protein to jump from animal to human, to become the UK variant that evolved from a patient treated with convalescent plasma or SA variant that is less effective on Spike only vaccine...https://t.co/6gDdw4VVXm
@JonathanPosto17 @dirtyboyg @BallouxFrancois ChAd-Ox1- In the primary end-point analysis, mild-to-moderate C-19, a VE of 21.9% (95% confidence interval [CI]). Where 92.9% of infections were caused by B.1.351; vaccine efficacy against B1.351, was 10.4% even with 2-doses https://t.co/9o9NtxVY11
@DocDellaire I haven’t seen results for Pfizer against B1351 ... but this is looking bad. https://t.co/ZvQZBvKx21
Astra Zenecan rokote ei suojaa Etelä-Afrikan varianttia B.1.351 vastaan. Efficacy = 10.4 prosenttia. Onko @THLorg ottanut tämän huomioon? 2/x https://www.nejm.org/doi/full/10.1056/NEJMoa2102214?query=featured_home
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
RT @matiere: NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
NEJM誌から AZ社のワクチンは南アの変異株には期待薄：日経メディカル https://t.co/cC1NDjX8z8 南アフリカでの臨床試験からB.1.351株に対する効果の中間解析 https://t.co/ZlLh4beKpk
うおーっと https://t.co/2nZZmfYQC5
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/nPOZAZQip4
Ainda mais preocupante, quando testaram os anticorpos induzidos pela vacina da AstraZeneca, para neutralizar esta variante, a capacidade de neutralização caiu significantemente + https://t.co/xbXxVu77sj https://t.co/DA5Z0waruw
RT @monarabia32: @BTEMB @florencedesruol @R_Bachelot Et ce même chef de Réa qui vend le vaccin Astrazeneca a oublié de dire que c'est parei…
@BTEMB @florencedesruol @R_Bachelot Et ce même chef de Réa qui vend le vaccin Astrazeneca a oublié de dire que c'est pareil pour l'inefficacité sur le variant sud africain https://t.co/OiVkTjDbpZ
@docdu16 Il n'a pas d'excuse de pas s'informer et désinformer: une étude randomisée en double aveugle a conclu : "A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant." https://t.co/OiVkTjDbpZ
Trending on PubMed: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. https://t.co/onIFQ7MBMf
New article: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/uDjbObl67f
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
@MoniquePlaza3 @ArthurTezlat Quel crédit accordé aux ignorances in- ou volontaires de ceux qui cautionnent un vaccin à tout prix , ici Pr Fischer :https://t.co/w6GEFokBTB Avec des ESI graves rapportés et une efficacité sur les variants faible selon cette étude randomisée.1/ https://t.co/OiVkTjDbpZ
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
@hirosetakao 同ワクチンはウイルスベクターワクチン（https://t.co/SlxCsGR5g9）なので、同じ技術を用いたアストラゼネカ製ワクチンと同様、南ア型変異株に効果が期待できない可能性もありますね。https://t.co/139Tl0hFYr
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant - PubMed https://t.co/zxQphgluxq
これは衝撃的な内容です。 アストラゼネカ製ワクチンでは、南アフリカ型変異株（B.1.351）による軽症から中等症のCovid-19の予防効果は乏しい。とのレポートが出ました。 #新型コロナウイルス #コロナ #COVID19 #新型コロナ #ワクチン https://t.co/FKJFBG7dG8
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
RT @syuichiao89: アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得ら…
アストラゼネカ製ワクチン、コロナ変異株にほとんど効果なし。 https://t.co/139Tl0zgPZ ChAdOx1 nCoV-19ワクチンを2回接種しても、B.1.351変異体による軽度から中等度のCovid-19に対する防御効果は得られなかった。
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
#Yoh_Yasushi_Check ちょっと変異株に対しては厳しいみたい、ワクチン。 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/pAH0iTW71Q
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
RT @Laurie_Garrett: This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate C…
This: "Two doses of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine did not show protection against mild-to-moderate COVID-19 among people infected with the B.1.351 variant in a multicenter randomized trial in South Africa." https://t.co/37JPxvdmNT
Link zur Publikation : https://t.co/R0rE2AhyvO
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/au3zGbPPxl https://t.co/OgGpgK2RJw
New article: Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant https://t.co/8qxjotSxey #coronavirus #COVID19 #2019ncov https://t.co/YQeofEyVtN
PV
LG
DR
SY
青発
MV
BS
SW
JM
JA
HG
AS
PP
T
VL
JT
J
PP
SK
Ä
M
AS
B
TH
SP
PL
KK
PE
HE
T
MK
KR
SH
TP
KH
KL
SM
HP
MN
TE
H
P
YN
J
B
JL
DB
SC
H
PN
C
M
S
EP
E
RS
SM
RR
E
TP
ST
SG
OE
JC
W
HG
AM
JL
PC
D
C
SC
S
M
PP
N
N
TC
RB
SN
JW
AE
MM
ほな
M
H
Y
ツ
お
五R
LE
M
C
陸
YN
笑
H
川
P
田脱
聖
お
風
M
LP
R
ンナ
朝
D
R
B
りT
HO
水カ
雲
ぷ
B
み
川
あA
H
T
ゴ
S
ま
天
だく
C
B
ぐ
コ
Ａ
R
WT
わ
M
KE
GF
め
フF
SS
YS
き
H
教
HB
ニ
BV
ア
接
イ
改良
ヨ
M慧
めS
お
H
Sシ
宙
DD
タ
チ
R
IP
BB
ほ
ぱ
ま
C
RA
名
IS
G
ML
YA
K
CL
PE
EG
N
นม
G
M
M
SV
M
GS
JV
S
園一
黒猫
し
مف
ما
M
M
MB
T隆
E
DO
S
手洗
フ
し
UC
た
小
CC
B
HY
べ
Mめ
フ
にN
S
BE
紗す
FP
T
I
ど
鳥
老
黒
FP
NB
ム
に
ハ
天A
M
M
MX
P
ぷ
駄
M
石
天
P
り
RI
SR
CO
R
L
KN
相B
T
も
M
ウ
M
う
鬼療
飯
D
うテ
ろ
大
セ
フ
C
医M
G
Y
日
M
醤
D
DR
PT
P
紅
U
怜社
中N
バ
臨C
Pラ
暑
AM
JS
JH
T
SM
PS
J
SM
MP
GG
Kב
R
K
OS
A
BJ
楊や
N
S
IH
TB
MM
I
DB
CM
KD
PI
KR
AA
GP
E
JS
B
O
N
RK
CB
RS
SF
DS
LL
PS
H
CR
KH
CG
NV
D
N
EE
C
TL
CS
VT
V
J
MA
NC
CF
KM
G
R
N